SG11201704521SA - Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors - Google Patents

Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors

Info

Publication number
SG11201704521SA
SG11201704521SA SG11201704521SA SG11201704521SA SG11201704521SA SG 11201704521S A SG11201704521S A SG 11201704521SA SG 11201704521S A SG11201704521S A SG 11201704521SA SG 11201704521S A SG11201704521S A SG 11201704521SA SG 11201704521S A SG11201704521S A SG 11201704521SA
Authority
SG
Singapore
Prior art keywords
thieno
pyrrol
derivatives
erk inhibitors
erk
Prior art date
Application number
SG11201704521SA
Other languages
English (en)
Inventor
Guillermo S Cortez
Sajan Joseph
Johnathan Alexander Mclean
William T Mcmillen
Michael John Rodriguez
Gaiying Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201704521SA publication Critical patent/SG11201704521SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201704521SA 2014-12-22 2015-12-16 Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors SG11201704521SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462095185P 2014-12-22 2014-12-22
PCT/US2015/065940 WO2016106029A1 (fr) 2014-12-22 2015-12-16 Dérivés de thiéno[2,3-c]pyrrol-4-one utilisés en tant qu'inhibiteurs de erk

Publications (1)

Publication Number Publication Date
SG11201704521SA true SG11201704521SA (en) 2017-07-28

Family

ID=55135525

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704521SA SG11201704521SA (en) 2014-12-22 2015-12-16 Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors

Country Status (44)

Country Link
US (3) US9469652B2 (fr)
EP (1) EP3237423B1 (fr)
JP (1) JP6445701B2 (fr)
KR (1) KR101917972B1 (fr)
CN (1) CN107108648B (fr)
AR (1) AR102977A1 (fr)
AU (1) AU2015369983C1 (fr)
BR (1) BR112017011130A2 (fr)
CA (1) CA2966559C (fr)
CL (1) CL2017001514A1 (fr)
CO (1) CO2017005217A2 (fr)
CR (1) CR20170182A (fr)
CY (1) CY1121831T1 (fr)
DK (1) DK3237423T3 (fr)
DO (1) DOP2017000122A (fr)
EA (1) EA031659B1 (fr)
EC (1) ECSP17038500A (fr)
ES (1) ES2738406T3 (fr)
GT (1) GT201700134A (fr)
HR (1) HRP20191268T1 (fr)
HU (1) HUE045933T2 (fr)
IL (1) IL252065B (fr)
JO (1) JO3596B1 (fr)
LT (1) LT3237423T (fr)
MA (1) MA41251B1 (fr)
MD (1) MD3237423T2 (fr)
ME (1) ME03490B (fr)
MX (1) MX371206B (fr)
MY (1) MY178426A (fr)
NZ (1) NZ731531A (fr)
PE (1) PE20171043A1 (fr)
PH (1) PH12017501155B1 (fr)
PL (1) PL3237423T3 (fr)
PT (1) PT3237423T (fr)
RS (1) RS59015B1 (fr)
SG (1) SG11201704521SA (fr)
SI (1) SI3237423T1 (fr)
SV (1) SV2017005443A (fr)
TN (1) TN2017000233A1 (fr)
TR (1) TR201909887T4 (fr)
TW (1) TWI704151B (fr)
UA (1) UA119686C2 (fr)
WO (1) WO2016106029A1 (fr)
ZA (1) ZA201702786B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57058B1 (sr) 2013-10-03 2018-05-31 Kura Oncology Inc Ekr inhibitori i postupci primene
CN107074874B (zh) 2014-12-22 2019-04-23 伊莱利利公司 Erk抑制剂
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑
SG10201912959QA (en) 2015-10-21 2020-02-27 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
WO2018005234A1 (fr) * 2016-06-29 2018-01-04 Eli Lilly And Company Combinaison d'un composé inhibiteur d'erk1/2 avec la gemcitabine ou avec la gemcitabine et nab-paclitaxel pour utilisation dans le traitement du cancer du pancréas
WO2018081204A1 (fr) * 2016-10-26 2018-05-03 Li George Y N-(5-((4-éthylpipérazine-1-yl)méthyl) pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-méthyl-1h-benzo[d]imidazol-6-yl)pyrimidin-2-amine deutéré
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
WO2019101182A1 (fr) 2017-11-24 2019-05-31 Janssen Pharmaceutica Nv Composés de pyrazolopyridinone
KR20210006365A (ko) * 2018-04-09 2021-01-18 쥐원 쎄라퓨틱스, 인크. 구동 종양원성 돌연변이를 갖는 암의 치료
CA3101117A1 (fr) * 2018-05-22 2019-11-28 Js Innomed Holdings Ltd. Composes heterocycliques utilises en tant qu'inhibiteurs de kinase, compositions comprenant le compose heterocyclique, et leurs procedes d'utilisation
TW202038957A (zh) 2018-12-21 2020-11-01 日商第一三共股份有限公司 抗體-藥物結合物與激酶抑制劑之組合
ES2944857T3 (es) * 2019-03-27 2023-06-26 Lilly Co Eli Sales del compuesto 5,6-dihidro-4H-tieno[2,3-c]pirrol-4-ona como inhibidores de ERK
US20220213119A1 (en) * 2019-03-28 2022-07-07 Jiangsu Hengrui Medicine Ca, Lid. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
BR112021018924A2 (pt) * 2019-03-29 2022-02-01 Jiangsu Hengrui Medicine Co Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
EP3968995A1 (fr) * 2019-05-16 2022-03-23 Eli Lilly and Company Triple association d'un inhibiteur d'erk1/2, d'un inhibiteur de braf et d'un inhibiteur de l'egfr, destinée à être utilisée dans le traitement du cancer colorectal positif pour la mutationde brafv600e
CN112457326B (zh) * 2019-09-06 2022-02-15 上海凌达生物医药有限公司 一类芳香杂环并内酰胺类化合物、制备方法和用途
AU2020394767B2 (en) * 2019-12-06 2023-05-25 D3 Bio (Wuxi) Co., Ltd. Spiro compound serving as ERK inhibitor, and application thereof
CN110950876B (zh) * 2019-12-10 2021-08-17 上海凌达生物医药有限公司 一类呋喃并内酰胺类化合物、制备方法和用途
WO2021216777A1 (fr) * 2020-04-21 2021-10-28 The Trustees Of The Stevens Institute Of Technology Inhibiteurs d'erk pour thérapie anticancéreuse
CN114315837B (zh) * 2020-09-29 2023-06-16 江苏恒瑞医药股份有限公司 一种erk抑制剂的结晶形式及其制备方法
EP4223758A4 (fr) * 2020-09-29 2024-04-03 Jiangsu Hengrui Pharmaceuticals Co Ltd Forme cristalline d'un dérivé pyrrolo-hétérocyclique et son procédé de préparation
WO2023274256A1 (fr) * 2021-06-28 2023-01-05 南京明德新药研发有限公司 Composés thiazole-lactame-spirohétérocycliques et leurs applications
CA3238655A1 (fr) * 2021-11-15 2023-05-19 Erasca, Inc. Inhibiteurs thiophenes de ulk1/2 et leur utilisation
WO2023137297A2 (fr) * 2022-01-11 2023-07-20 Suvalent Therapeutics, Inc. Inhibiteurs de 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023048A1 (de) * 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (fr) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Composes de pyrazole utiles comme inhibiteurs de proteine kinase
ES2362931T3 (es) 2002-03-04 2011-07-15 Imclone Llc Anticuerpos humanos específicos contra kdr y usos de los mismos.
AU2003295396B2 (en) * 2002-11-04 2009-02-26 Vertex Pharmaceuticals Incorporated Heteroaryl-pyramidine derivatives as JAK inhibitors
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
EP1948647A1 (fr) * 2005-11-03 2008-07-30 SGX Pharmaceuticals, Inc. Modulateurs de kinase de type pyrimidinylthiophène
US8697694B2 (en) 2008-08-20 2014-04-15 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CN102245600A (zh) * 2008-10-08 2011-11-16 百时美施贵宝公司 吡咯烷酮黑色素浓集激素受体-1拮抗剂
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
CA2809662C (fr) * 2010-09-01 2019-04-16 Gilead Connecticut, Inc. Pyridazinones, leur procede de fabrication et leur procede d'utilisation
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
UA116774C2 (uk) * 2012-03-01 2018-05-10 Еррей Біофарма Інк. Інгібітори серин/треонінкінази
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
EA201500370A1 (ru) * 2012-09-28 2015-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
CN107074874B (zh) * 2014-12-22 2019-04-23 伊莱利利公司 Erk抑制剂
TWI704151B (zh) * 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑

Also Published As

Publication number Publication date
MD3237423T2 (ro) 2019-11-30
HUE045933T2 (hu) 2020-01-28
UA119686C2 (uk) 2019-07-25
CN107108648B (zh) 2019-07-12
PH12017501155A1 (en) 2017-11-27
TN2017000233A1 (en) 2018-10-19
TWI704151B (zh) 2020-09-11
SI3237423T1 (sl) 2019-08-30
EP3237423B1 (fr) 2019-06-05
ME03490B (fr) 2020-01-20
USRE48635E1 (en) 2021-07-13
AU2015369983A1 (en) 2017-05-25
SV2017005443A (es) 2018-08-27
EA031659B1 (ru) 2019-02-28
PT3237423T (pt) 2019-08-21
TW201632530A (zh) 2016-09-16
AU2015369983C1 (en) 2019-02-21
DK3237423T3 (da) 2019-07-22
CA2966559A1 (fr) 2016-06-30
US9526733B1 (en) 2016-12-27
EA201791133A1 (ru) 2017-10-31
RS59015B1 (sr) 2019-08-30
PL3237423T3 (pl) 2020-01-31
US20160176896A1 (en) 2016-06-23
MY178426A (en) 2020-10-13
CY1121831T1 (el) 2020-07-31
US9469652B2 (en) 2016-10-18
GT201700134A (es) 2018-11-23
IL252065A0 (en) 2017-07-31
BR112017011130A2 (pt) 2017-12-26
IL252065B (en) 2020-08-31
KR20170083145A (ko) 2017-07-17
CO2017005217A2 (es) 2017-09-20
HRP20191268T1 (hr) 2019-11-01
TR201909887T4 (tr) 2019-07-22
AU2015369983B2 (en) 2018-08-23
ZA201702786B (en) 2019-02-27
PH12017501155B1 (en) 2017-11-27
CR20170182A (es) 2017-06-21
PE20171043A1 (es) 2017-07-19
CA2966559C (fr) 2019-06-18
US20160375030A1 (en) 2016-12-29
ECSP17038500A (es) 2017-12-01
JP6445701B2 (ja) 2018-12-26
EP3237423A1 (fr) 2017-11-01
JP2017538768A (ja) 2017-12-28
LT3237423T (lt) 2019-08-26
MX371206B (es) 2020-01-22
KR101917972B1 (ko) 2018-11-12
MA41251A (fr) 2017-11-01
ES2738406T3 (es) 2020-01-22
CL2017001514A1 (es) 2018-02-09
MX2017008242A (es) 2017-10-06
MA41251B1 (fr) 2019-09-30
DOP2017000122A (es) 2017-06-15
AR102977A1 (es) 2017-04-05
CN107108648A (zh) 2017-08-29
JO3596B1 (ar) 2020-07-05
WO2016106029A1 (fr) 2016-06-30
NZ731531A (en) 2018-12-21

Similar Documents

Publication Publication Date Title
IL252065A0 (en) Thiano[2,3-c]pyrrol-4-ion derivatives as erk inhibitors
HK1244804A1 (zh) 4h-吡咯並[3，2-c]吡啶-4-酮衍生物
IL256265B (en) 3-tetrazolyl-benzene-2,1-disulfonamide derivatives as metallo-beta-lactamase inhibitors
IL244702B (en) Novel histories of 3-(h1-pyrazol-4-yl)-h1-pyrrolo[3,2-c]pyridine as nick inhibitors
ZA201808257B (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
IL251779B (en) Novel thianopyrimidine histories as nik inhibitors
EP3394068A4 (fr) Inhibiteurs de tdo2
HK1246779A1 (zh) 作為磷酸肌醇3-激酶抑制劑的色烯衍生物
EP3233858A4 (fr) Inhibiteurs d'erk
EP3097101A4 (fr) Dérivés d'isoquinoline utilisés comme inhibiteurs de mgat2
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
EP3233859A4 (fr) Inhibiteurs d'erk
HK1254355A1 (zh) Bace1抑制劑2-氨基-7a-苯基-3，4，4a，5，7，7a-六氫呋喃並[3，4-b]吡啶
HUE038944T2 (hu) Tiokromeno[2,3-c]kinolin-12-on származékok és topoizomeráz inhibitorként való alkalmazásuk
HK1206334A1 (en) Dehydrothiamine [2,3-c]quinoline-12-ketone derivatives, and preparation method and application thereof [2,3-c]-12-
IL235077A0 (en) New derivatives of thiochromano[2,3-c]quino lin-12-one, its preparation method and application
SG10201406318YA (en) Novel thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof